Kamada (NASDAQ:KMDA) Stock Price Passes Below 200 Day Moving Average - Here's What Happened

Key Points

• Kamada Ltd. (NASDAQ: KMDA) shares dipped below their 200-day moving average of $7.07, trading as low as $6.92 before closing at $7.05 on Thursday.
• Analysts maintain a positive outlook for Kamada, with two offering a "Buy" rating and one a "Hold," alongside a consensus price target of $13.00.
• The company reported $0.13 EPS for the last quarter, surpassing analyst expectations, but its revenue fell significantly short of estimates at $44.75 million.

Kamada Ltd. (NASDAQ:KMDA - Get Free Report) shares crossed below its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $7.07 and traded as low as $6.92. Kamada shares last traded at $7.05, with a volume of 28,312 shares trading hands.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the company. Benchmark reissued a "buy" rating and issued a $15.00 target price on shares of Kamada in a research note on Thursday, May 15th. Wall Street Zen raised Kamada from a "buy" rating to a "strong-buy" rating in a report on Wednesday, May 21st. Finally, Sidoti raised Kamada to a "hold" rating in a research note on Thursday, May 8th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $13.00.

Kamada Trading Down 0.4%

The business has a 50-day moving average of $7.48 and a 200 day moving average of $7.07. The firm has a market capitalization of $404.01 million, a P/E ratio of 20.66, a price-to-earnings-growth ratio of 0.76 and a beta of 0.93.

Kamada (NASDAQ:KMDA - Get Free Report) last released its earnings results on Wednesday, August 13th. The biotechnology company reported $0.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.09 by $0.04. The company had revenue of $44.75 million during the quarter, compared to analyst estimates of $158.59 million. Kamada had a return on equity of 7.41% and a net margin of 11.22%. Kamada has set its FY 2025 guidance at EPS. As a group, research analysts forecast that Kamada Ltd. will post 0.23 EPS for the current year.

Hedge Funds Weigh In On Kamada

Institutional investors and hedge funds have recently bought and sold shares of the company. Huntleigh Advisors Inc. purchased a new stake in shares of Kamada during the first quarter worth $863,000. Geode Capital Management LLC lifted its position in shares of Kamada by 5.6% during the fourth quarter. Geode Capital Management LLC now owns 29,289 shares of the biotechnology company's stock worth $178,000 after acquiring an additional 1,549 shares in the last quarter. JPMorgan Chase & Co. purchased a new stake in shares of Kamada during the fourth quarter worth $67,000. NewEdge Advisors LLC lifted its position in shares of Kamada by 54.2% during the fourth quarter. NewEdge Advisors LLC now owns 23,496 shares of the biotechnology company's stock worth $143,000 after acquiring an additional 8,260 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership purchased a new stake in shares of Kamada during the second quarter worth $472,000. 20.38% of the stock is owned by institutional investors.

About Kamada

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.